UNSPSC 51434303: Bendroflumethiazide

This classification denotes a thiazide diuretic with the molecular formula C15H14F3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q52X6ICJI, chemically known as 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as bendroflumethiazide, which bears US NIH Compound Identifier 2315. European Medicines Agency schedules Bendroflumethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05711MIG.

UNSPSC 51434303 Bendroflumethiazide is a Commodity code representing a specific pharmaceutical product—a thiazide diuretic used in emergency and clinical settings—that state and local governments procure as part of broader medication supply contracts for emergency services, health systems, and pharmacy benefit programs. State and local agencies acquire this medication through competitive sealed-bid and cooperative purchasing arrangements that bundle it with other pharmaceuticals into multi-product agreements; the actual solicitations show government buyers treating individual drugs as line items within larger Advanced Life Support medications contracts, generic pharmaceutical master agreements, or direct-to-manufacturer pharmacy initiatives rather than purchasing bendroflumethiazide in isolation. Issuing bodies include city fire departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances administering contracts on behalf of state and local facilities across multiple jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department posted IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000—the solicitation bundles bendroflumethiazide-class drugs with Labetalol, Epinephrine, Adenosine, and Diltiazem as sealed-bid line items. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to bypass traditional pharmacy benefit managers for prescription sourcing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, solicited an RFP posted January 20, 2026, with responses due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota, Oregon, and participating jurisdictions; the contract requires vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements. Tampa's SLBE sheltered-market designation offers a 5 percent bid discount, and MMCAP's RFP weights price competitiveness at 75 percent of the evaluation score.